Phenytoin
What is Dilantin-125 (Phenytoin)?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: This study is being done to understand how the body processes the study drug (BGB-58067) when it is taken together with other medicines. BGB-58067 is mainly broken down in the body by a liver enzyme called CYP3A. Some medicines can affect how this enzyme works. For example, certain medicines can increase the production of the enzyme (called inducers), while others can block or inhibit its activity...
Summary: The purpose of this study is to assess the effect of multiple doses of phenytoin, a strong cytochrome P450 (CYP)3A4 inducer, and itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetic (PK) profile of DAK539 (hereafter referred to as pelabresib) after a single dose in healthy participants. In addition, the safety and tolerability of a single dose of pelabresib with and without the co-admin...
Summary: The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin. The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the co...
Related Latest Advances
Brand Information
- A history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins
- A history of prior acute hepatotoxicity attributable to phenytoin
- Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.
- Withdrawal Precipitated Seizure, Status Epilepticus
- Suicidal Behavior and Ideation
- Serious Dermatologic Reactions
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity
- Hypersensitivity
- Cardiac Effects
- Angioedema
- Hepatic Injury
- Hematopoietic Complications
- Effects on Vitamin D and Bone
- Exacerbation of Porphyria
- Teratogenicity and Other Harm to the Newborn
- Hyperglycemia

(phenytoin, USP)
Oral Suspension
Adults, 1 teaspoonful (5 mL) three times
daily; pediatric patients, see package
insert.
calibrated measuring device is
recommended to measure and deliver the
prescribed dose accurately. A household
teaspoon or tablespoon is not an
adequate measuring device.


